ArticleInfectious diseases and therapy2022

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension.

Robert S Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.